Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma

NCT07618793 | Not Yet Recruiting Phase 2

• 2 other identifiers: KS2026139CFH-2026-2-2014
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn if adding intermittent hypoxic training (IHT) to standard neoadjuvant chemo-immunotherapy can increase the pathologic complete response (pCR) rate in patients aged 18 to 75 of both sexes with resectable stage II-IIIA lung squamous cell carcinoma. The main questions it aims to answer are:Can the addition of IHT to standard neoadjuvant chemo-immunotherapy significantly improve the pathologic complete response (pCR) rate compared to standard therapy alone? Is IHT safe and well-tolerated in this perioperative setting, and can it improve 2-year recurrence-free survival (RFS) without increasing complications? Researchers will compare the experimental group (standard neoadjuvant chemo-immunotherapy combined with IHT) to the control group (standard neoadjuvant chemo-immunotherapy alone) to see if the combination safely enhances anti-tumor immune responses, improves tumor regression, and extends long-term survival. Participants will:Receive standard neoadjuvant chemo-immunotherapy for 4 cycles (21 days per cycle), consisting of nab-paclitaxel, carboplatin, and pembrolizumab. Undergo Intermittent Hypoxic Training (IHT) if randomized to the experimental group, using the FLY-2265 low oxygen system (13% $FiO\_2$ for 5 minutes followed by 21% $FiO\_2$ for 5 minutes per cycle; 10 cycles per session, twice daily) for 7 consecutive days starting on Day 1 of each chemo-immunotherapy cycle. Undergo surgery (VATS lobectomy and systematic lymph node dissection) 3 to 4 weeks after the completion of the 4th cycle, provided that the disease has not progressed. Complete regular post-operative follow-up visits (including chest CT scans, brain MRIs, bone scans, tumor markers, and peripheral blood immune monitoring) for up to 5 years to evaluate long-term outcomes.

Conditions

Lung Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung (NSCLC)

Keywords

Lung Squamous Cell Carcinoma; Intermittent Hypoxic Training; Neoadjuvant Chemoimmunotherapy; CD8-Positive T-Lymphocytes; Non-Small Cell Lung Cancer; Pathologic Complete Response

Outcome Measures

Primary Outcomes (1)

• Pathologic Complete Response (pCR) Rate

  The percentage of participants who achieve pathologic complete response, defined as the complete disappearance of all invasive tumor cells in the completely resectable lung cancer specimen and all sampled regional lymph nodes (ypT0N0) following neoadjuvant therapy.

  At the time of surgery (approximately 3 to 4 weeks after the completion of the 4th cycle of neoadjuvant therapy).

Secondary Outcomes (4)

• Major Pathological Response (MPR) Rate

  At the time of surgery (approximately 3 to 4 weeks after the completion of the 4th cycle of neoadjuvant therapy).

• Incidence of Treatment-Emergent Adverse Events (TEAEs)

  From the start of neoadjuvant therapy up to 30 days after surgery (approximately 5 months).

• 2-Year Recurrence-Free Survival (RFS) Rate

  2 years post-surgery.

• Changes in Peripheral Blood Immune Cell Subsets

  Baseline (before therapy) and prior to surgery (approximately 12 weeks after baseline).

Study Arms (2)

Intermittent Hypoxic Training + Chemo-immunotherapy

EXPERIMENTAL

Participants will receive standard neoadjuvant chemo-immunotherapy (nab-paclitaxel + carboplatin + pembrolizumab) for 4 cycles (21 days per cycle). Concurrently, participants will undergo Intermittent Hypoxic Training (IHT) using the FLY-2265 system (13% FiO2 for 5 min, 21% FiO2 for 5 min per cycle; 10 cycles/session, twice daily) for 7 consecutive days starting on Day 1 of each chemo-immunotherapy cycle. Surgery will be performed 3-4 weeks after completing the 4th cycle.

Device: Intermittent Hypoxic Training (IHT); Combination Product: Standard Neoadjuvant Chemo-immunotherapy

Standard Neoadjuvant Chemo-immunotherapy Alone

ACTIVE COMPARATOR

Participants will receive standard neoadjuvant chemo-immunotherapy alone for 4 cycles (21 days per cycle). The regimen consists of nab-paclitaxel, carboplatin, and pembrolizumab at standard clinical doses, identical to the experimental group. No intermittent hypoxic training will be administered. Surgery will be performed 3-4 weeks after completing the 4th cycle.

Combination Product: Standard Neoadjuvant Chemo-immunotherapy

Interventions

Standard Neoadjuvant Chemo-immunotherapy COMBINATION_PRODUCT

Participants will receive standard clinical doses of neoadjuvant chemo-immunotherapy for 4 cycles (21 days per cycle) prior to surgery. The regimen includes: 1) Nab-paclitaxel; 2) Carboplatin; 3) Pembrolizumab. All agents will be administered via intravenous infusion according to standard clinical oncology guidelines.

Also known as: Nab-paclitaxel, Carboplatin, Pembrokizumab

Intermittent Hypoxic Training + Chemo-immunotherapy; Standard Neoadjuvant Chemo-immunotherapy Alone

Intermittent Hypoxic Training (IHT) DEVICE

Participants will undergo Intermittent Hypoxic Training (IHT) using the FLY-2265 low oxygen system. The training protocol consists of cycles of inhaling 13% FiO2 (fraction of inspired oxygen) for 5 minutes, followed by 21% FiO2 (room air) for 5 minutes. Each session comprises 10 cycles, administered twice daily, for 7 consecutive days. This 7-day training course starts on Day 1 of each 21-day neoadjuvant treatment cycle, for a total of 4 courses.

Intermittent Hypoxic Training + Chemo-immunotherapy

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age between 18 and 75 years old (inclusive), regardless of sex.
• Diagnosed with histologically confirmed stage II-IIIA (according to the AJCC 8th edition staging system) squamous cell lung carcinoma.
• The primary tumor is evaluated by a multidisciplinary team (MDT) and deemed completely resectable.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
• Life expectancy of at least 6 months.
• Adequate organ, bone marrow, and coagulation functions, meeting the following laboratory criteria within 7 days prior to enrollment:
• Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L;
• Platelet count \>= 100 x 10\^9/L;
• Hemoglobin \>= 90 g/L;
• Total bilirubin \<= 1.5 x upper limit of normal (ULN);
• Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) \<= 2.5 x ULN;
• Serum creatinine \<= 1.5 x ULN, or creatinine clearance \>= 50 mL/min;
• International normalized ratio (INR) and activated partial thromboplastin time (APTT) \<= 1.5 x ULN.
• Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and agree to use effective contraception during the study and for at least 6 months after the last dose. Male participants must agree to use effective contraception during the study and for at least 6 months after the last dose.
• Participant understands the study protocol, voluntarily participates, and signs the written Informed Consent Form (ICF).

You may not qualify if:

• Histologically confirmed small cell lung cancer, adeno-squamous carcinoma, large cell neuroendocrine carcinoma, or adenocarcinoma (including components of these types).
• Patients with driver gene mutations that have approved targeted therapies available (e.g., EGFR mutations, ALK rearrangements, ROS1 fusions, etc.).
• Prior systemic antitumor therapy for lung cancer, including chemotherapy, radiotherapy, immunotherapy, targeted therapy, or definitive surgical resection.
• Active, known, or suspected autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis), or a history of autoimmune disease within the past 2 years.
• History of other malignant tumors within the past 5 years, except for adequately treated cured skin basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ (e.g., cervical carcinoma in situ).
• Severe cardiovascular or cerebrovascular diseases, including but not limited to:
• Myocardial infarction or unstable angina within the past 6 months;
• New York Heart Association (NYHA) Class III or IV congestive heart failure;
• Clinically significant ventricular arrhythmia or poorly controlled symptomatic arrhythmia;
• Stroke or transient ischemic attack (TIA) within the past 6 months.
• Poorly controlled hypertension (systolic blood pressure \>= 160 mmHg and/or diastolic blood pressure \>= 100 mmHg despite standard antihypertensive therapy).
• Chronic obstructive pulmonary disease (COPD) or other respiratory diseases with severe lung function impairment (e.g., FEV1 \< 50% predicted value, or requiring long-term home oxygen therapy).
• Active infections requiring systemic intravenous anti-infective treatment within 2 weeks prior to enrollment (e.g., severe pneumonia, bacteremia), or active tuberculosis infection.
• Known history of human immunodeficiency virus (HIV) infection, or active Hepatitis B (HBV DNA \>= 500 IU/mL or copy number above detection limit) or active Hepatitis C (HCV RNA positive).
• History of interstitial lung disease (ILD), drug-induced pneumonitis, radiation pneumonitis requiring steroid treatment, or evidence of active pneumonitis.

Sponsors & Collaborators

• zhang yi: lead
• Capital Medical University: collaborator

Study Sites (1)

Xuanwu Hospital, Capital Medical University

Beijing, Beijing Municipality, 100053, China

Location

MeSH Terms

Conditions

Carcinoma; Carcinoma, Non-Small-Cell Lung; Pathologic Complete Response

Interventions

130-nm albumin-bound paclitaxel; Carboplatin

Condition Hierarchy (Ancestors)

Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Lung Diseases; Respiratory Tract Diseases; Disease Progression; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals

Central Study Contacts

Yi Zhang, PhD

CONTACT

+86-13141370703; zhangyixwhosp@xwh.ccmu.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor and Chief Physician

Model Details: This is a prospective, randomized, open-label, parallel-controlled, single-center clinical trial. Eligible participants with resectable stage II-IIIA lung squamous cell carcinoma will be randomly assigned in a 1:1 ratio to either the experimental group (receiving standard neoadjuvant chemo-immunotherapy combined with intermittent hypoxic training) or the control group (receiving standard neoadjuvant chemo-immunotherapy alone).

Study Record Dates

• First Submitted: May 25, 2026
• First Posted: June 1, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2028
• Last Updated: June 1, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)